Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Neuro-Oncology"
DOI: 10.1007/s11060-017-2466-0
Abstract: A single institution retrospective evaluation of nivolumab following disease progression on bevacizumab in adults with recurrent glioblastoma (GBM) with an objective of determining progression free survival (PFS). There is no accepted therapy for recurrent GBM… read more here.
Keywords: gbm; nivolumab; recurrent glioblastoma; patients recurrent ... See more keywords
Nivolumab-induced immune thrombocytopenia in a patient with malignant pleural mesothelioma
Sign Up to like & getrecommendations! Published in 2020 at "Respiratory Medicine Case Reports"
DOI: 10.1016/j.rmcr.2020.101170
Abstract: Malignant pleural mesothelioma (MPM) is a rare and highly aggressive tumor. Nivolumab showed durable antitumor effect in patients with recurrent MPM and was approved for those patients in Japan in 2018. Immune related adverse event… read more here.
Keywords: pleural mesothelioma; malignant pleural; nivolumab; nivolumab induced ... See more keywords
Nivolumab dans le traitement du cancer du poumon métastatique en France : analyse des 10 621 patients traités en 2015 et 2016 à partir des données du PMSI
Sign Up to like & getrecommendations! Published in 2018 at "Revue Des Maladies Respiratoires"
DOI: 10.1016/j.rmr.2017.10.224
Abstract: Introduction Nivolumab est indique dans le traitement des patients atteints d’un cancer bronchique non a petites cellules (CBNPC) localement avance ou metastatique ayant progresse apres une chimiotherapie anterieure. Nivolumab a ete mis a disposition en… read more here.
Keywords: partir; 621 patients; nivolumab; dans traitement ... See more keywords
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial.
Sign Up to like & getrecommendations! Published in 2025 at "Nature medicine"
DOI: 10.1038/s41591-025-04032-8
Abstract: Based on RELATIVITY-047, nivolumab plus relatlimab is approved for advanced melanoma. Here, to address a current unmet need for more efficacious adjuvant regimens for completely resected melanoma, the phase 3, double-blind RELATIVITY-098 trial compared adjuvant… read more here.
Keywords: stage iii; relativity 098; plus relatlimab; nivolumab ... See more keywords
The efficacy and safety of Nivolumab combined with Ipilimumab in the immunotherapy of cancer: a meta-analysis
Sign Up to like & getrecommendations! Published in 2021 at "Immunopharmacology and Immunotoxicology"
DOI: 10.1080/08923973.2021.1924195
Abstract: Abstract Background and Objective: Nivolumab and Ipilimumab are immune checkpoint inhibitors. The combination of Nivolumab and Ipilimumab has been reported to have complementary effects in the treatment of metastatic melanoma. The combination therapy of Nivolumab… read more here.
Keywords: combination; efficacy safety; nivolumab; nivolumab combined ... See more keywords
Nivolumab combined docetaxel versus nivolumab in patients with previously treated nonsmall cell lung cancer: a phase 2 study
Sign Up to like & getrecommendations! Published in 2024 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000001569
Abstract: The current standard second-line treatment is immune checkpoint inhibitors monotherapy for nonsmall cell lung cancer (NSCLC) patients. The objective of this phase 2 study was to evaluate the efficacy and safety of nivolumab plus docetaxel… read more here.
Keywords: cancer; phase study; nivolumab; group ... See more keywords
Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-005620
Abstract: Fibrolamellar carcinoma (FLC) is a rare cancer of the liver that most commonly affects children and young adults. There is no clear standard of care for the disease, whose response to treatment seems to be… read more here.
Keywords: fibrolamellar carcinoma; nivolumab; ipilimumab; treatment ... See more keywords
Outcomes and Safety of Biweekly and Monthly Nivolumab in Patients with Metastatic Renal Cell Carcinoma and Dialysis: Three Case Reports and Literature Review
Sign Up to like & getrecommendations! Published in 2020 at "Urologia Internationalis"
DOI: 10.1159/000504515
Abstract: Nivolumab is a fully human immunoglobulin G4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody that selectively blocks the interaction between PD-1, which is expressed on activated T cells, and its ligands PD-L1 and PD-L2, which… read more here.
Keywords: renal cell; cell carcinoma; patients metastatic; nivolumab ... See more keywords
Response Rate and Prognostic Impact of Salvage Chemotherapy after Nivolumab in Patients with Advanced Gastric Cancer
Sign Up to like & getrecommendations! Published in 2020 at "Oncology"
DOI: 10.1159/000507219
Abstract: Objective: Nivolumab is recommended as a third-line treatment in patients with unresectable advanced or recurrent gastric cancer. Although recent studies have demonstrated the prognostic impact of salvage chemotherapy after immune checkpoint inhibitors in several malignancies,… read more here.
Keywords: gastric cancer; nivolumab; salvage chemotherapy;
Delayed immune thrombocytopenia after discontinuation of nivolumab therapy: A case report and literature review
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/1078155220981155
Abstract: Introduction Nivolumab, a programmed death-1(PD-1) inhibitor antibody, have demonstrated anti-tumor activity for multiple malignancies. Such immune checkpoint inhibitors induce novel and distinctive adverse effects, which are collectively named immune-related adverse events. Immune-related adverse events can… read more here.
Keywords: immune related; report; nivolumab; related adverse ... See more keywords
Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statuses
Sign Up to like & getrecommendations! Published in 2020 at "BMC Cancer"
DOI: 10.1186/s12885-020-07176-7
Abstract: Background Nivolumab has changed the treatment of advanced gastric cancer (AGC). Nivolumab shows better outcomes compared to best supportive care among AGC patients who received at least two prior regimens. However, there are no reliable… read more here.
Keywords: advanced gastric; group; nivolumab; cancer ... See more keywords